Follow us on Twitter
This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS
|| List of recent Leukemia-related patents
| Rna chimeras in human leukemia and lymphoma|
Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent rna fusions as diagnostic markers and clinical targets for leukemia..
| Markers associated with chronic lymphocytic leukemia prognosis and progression|
The present invention provides methods and devices related to markers (or biomarkers) associated with chronic lymphocytic leukemia (cll). Examples of these markers include drivers of cll progression.
| Use of chimeric anti-cd20 antibody as in vitro or in vivo purging agent in patients receiving bmt or pbsc transplant|
The use of anti-cd20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of b-cell-related diseases, e.g., b-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients..
|Therapeutic composition for treating cancers|
Disclosed herein is a composition that includes a novel combination of triterpenoids for the treatment or prophylaxis of a cancer. The triterpenoids includes at least ganoderic acid s (gas), ganoderic acid t (gat), ganoderic acid me (game), ganoderic acid r (gar), and ganodermic acid s (gmas).
|Combination therapy for mds|
Disclosed are compositions and methods for the treatment of disorders such as myelodysplastic syndrome (mds) and acute myeloid leukemia (aml). The disclosed methods include administering to an individual in need of such treatment a composition that may include an irak1/4 inhibitor.
|Use of fluorine-containing water soluble platinum complex in preparing drugs for prevention and treatment of cancers|
Disclosed in the present invention is the use of a fluorine-containing in preparing drugs for the prevention and treatment of tumors, said platinum complex being shown as formula (i). Experiments have demonstrated that the present fluorine-containing water soluble platinum complex is highly water soluble and exhibiting superior cytotoxicity and efficacy compare to the clinical platinum drugs.
|Tcl1 peptides for immunotherapy|
Provided are tcl1 peptides that bind to mhc i (hla-a2) on tumor cells or other antigen-presenting cells and are recognized by t-cell receptors on t cells. The tcl1 peptides may be therapeutically used to treat a cancer, such as a b cell malignancy, leukemia, or lymphoma.
|Method of treating and reducing the risk of acute myelogenous leukemia|
The present invention relates to methods and compositions for treating and reducing the risk of acute myelogenous leukemia (aml). In particular, the invention provides methods for identifying novel treatments for aml based on reproducible and detectable changes in aml1-eto acetylation.
|Histone deacetylase (hdac) inhibitors for the treatment of cancer|
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (hdac) inhibitor as described herein, for example, pxd-101.
|Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation|
Screening assays to identify compounds that may be useful for inhibiting and/or eliminating aml initiating cells using ahr modulators and/or the compounds of formula i or ii are also disclosed. The use of pharmaceutically acceptable agonists of the ahr for preventing or inhibiting minimal residual disease (mrd) in an aml patient is also disclosed..
|Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof|
The present invention relates to a cd43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a cd43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, and to its diagnostic and therapeutic application on acute leukemia and lymphoblastic lymphoma..
|Anti-human cd52 immunoglobulins|
The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human cd52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain.
|Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma|
The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-hodgkin's lymphomas (nhl) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers.
|Tyrosine, serine and threonine phosphorylation sites|
The invention discloses 155 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including aqua peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.. .
|Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging|
The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e.
|Inhibitors of c-fms kinase|
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
|Natural and synthetic compounds for treating cancer and other diseases|
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
|Cyclin a1-targeted t-cell immunotherapy for cancer|
Compositions and methods are provided for eliciting antigen-specific t-cell responses against human cyclin a1 (ccna1), which is herein identified as a leukemia-associated antigen based on its overexpression in acute myeloid leukemia (aml) including leukemia stem cells (lsc) and in immunologically privileged testis cells, but not in other normal cell types. Ccna1-derived peptide epitopes that are immunogenic for t-cells including ctl are disclosed, as are immunotherapeutic approaches using such peptides for vaccines and generation of adoptive transfer therapeutic cells..
|Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells|
The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (aml) and b-cell acute lymphoid leukemia (b-all). The invention also relates to at least one chimeric antigen receptor (car) specific to cd123, vectors comprising the same, and recombinant t cells comprising the cd123 car.
|Treatment of hematologic malignancies with an anti-cxcr4 antibody|
The present disclosure provides human monoclonal antibodies that bind specifically to cxcr4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a cxcr4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-cxcr4 antibody of the disclosure.
|Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia|
The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of b-precursor acute lymphoblastic leukemia (all) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy.. .
|Treatment of cancer with dihydropyrazino-pyrazines|
Provided herein are methods for treating or preventing chronic lymphocytic leukemia, comprising administering an effective amount of a dihydropyrazino-pyrazine compound to a patient having chronic lymphocytic leukemia.. .
|Achillea fragrantissima extract, method for preparing achillea fragrantissima extract and method for treating chronic myeloid leukemia|
An achillea fragrantissima extract for treating chronic myeloid leukemia cells is made by the following steps: washing a mass of achillea fragrantissima leaves and powdering the dried leaves. The leaves are dried over seven days and a kilo of the powder is extracted three times with methanol.
|Compositions and methods for treatment of cytomegalovirus|
The present disclosure provides compositions and methods useful for treating hcmv infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (vlps) which comprise one or more moloney murine leukemia virus (mmlv) core proteins and include one or more hcmv epitopes, such as, for example, from hcmv envelope glycoproteins gb and/or gh and/or tegument protein pp65.
|Cd44 monoclonal antibody for the treatment of b-cell chronic lymphocytic leukemia and other hematological malignancies|
Compositions including an antibody specific for cd44 are provided. These antibodies specifically bind to hematologic malignant cells.
|Methods of treating and preventing leukemia and other cancers of the blood and bone|
The present invention relates to preventing and treating leukemia and other cancers of the blood and bone, as well as disorders of the blood, by inhibiting gut-derived serotonin. The inhibition of the gut-derived serotonin is accomplished by inhibiting tph1, an enzyme responsible for the production of gut-derived serotonin.
|Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias|
The present invention relates to a method of treating a warm-blooded animal, especially a human, having mixed lineage leukemia (mll rearranged all) comprising administering to said animal a therapeutically effective amount of a staurosporine derivative, especially pkc412 or a pharmaceutically acceptable salt thereof, alone or in combination with further therapeutic measures, for example, those defined herein; to the use of a staurosporine derivative for the preparation of a medicament for the treatment of mll rearranged all; and to a commercial package comprising a staurosporine derivative together with instructions for its use in the treatment of mll rearranged all.. .
The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives.
|Zap-70 detection in chronic lymphocytic leukemia|
Detection of zap-70 expression provides important information about disease progression and overall survival in patients with chronic lymphocytic leukemia (cll). The invention provides methods for diagnosing cll in a subject, as well as methods for clearly distinguishing cll patients with aggressive form of the disease.
|Compositions and methods for cancer and cancer stem cell detection and elimination|
In alternative embodiments, the invention provides compositions and methods for inhibiting or ablating cancer stem cells. In alternative embodiments, the invention provides compositions and methods for inhibiting the action of double-stranded rna-specific adenosine deaminases, or adar, enzymes.
|Combination cancer therapy with an hsp90 inhibitor and an antimetabolite|
The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (i) 40 or (ia) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives.. .
|T cell receptor-like antibodies specific for a wti peptide presented by hla-a2|
The present invention provides antigen binding proteins that specifically bind to wilms' tumor protein (wt1), including humanized, chimeric and fully human antibodies against wt1, antibody fragments, chimeric antigen receptors (cars), fusion proteins, and conjugates thereof. The antigen binding proteins and antibodies bind to hla-a0201-restricted wt1 peptide.
|Pgam1 inhibitors and methods related thereto|
In certain embodiments, the disclosure relates to methods of treating or preventing a pgam1 mediated condition such as cancer or tumor growth comprising administering an effective amount of pgam1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof..
|Use of carbamide peroxide injection in preparation of virus inactivation medicaments for treating diseases|
The invention relates to the field of medicament use, in particular to the clinical use of carbamide peroxide injection series for virus inactivation in the treatment of blood vessel plaque, leukemia, aids and hepatitis, etc. The invention utilizes the affinity of photosensitizers to blood vessel plaque focus, leukemia cells, tumor, and/or virus, which is several times higher than that to normal tissues, so as to destroy focus cells or virus by generating sufficient singlet oxygen (1o2) under the effect of a method using laser, x-ray, ultrasound and medicament, etc., while in condition of using carbamide peroxide injection series.
|N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia|
The present invention relates to a method of treating chronic myelogenous leukemia in a subject comprising administering to the subject a compound, such as n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide, that inhibits the t315i mutation in bcr-abl tyrosine kinase, or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition comprising a compound such as n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide, that inhibits the t315i mutation in bcr-abl tyrosine kinase, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent..
Popular terms: [SEARCH]
Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol
Follow us on Twitter
This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.